Clinical Trial Update: An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

This clinical trial update discusses an extension study of Rozanolixizumab in pediatric Generalized Myasthenia Gravis patients, evaluating 6-week treatment cycl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: ENROLLING_BY_INVITATION